{'fraction_non_alphanumeric': 0.020713463751438434, 'fraction_numerical': 0.0, 'mean_word_length': 6.016129032258065, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Microbiota and Xenobiotics Reveal Links between Myopathy, Inflammaging and Glycolytic Metabolism

Environmental cues influence the risk and severity of myopathy and sarcopenia. Increased inflammation during ageing (i.e. inflammaging) has been proposed as a contributor sarcopenia. The source of age‐related inflammation is ill‐defined. Xenobiotics, including therapeutic drugs, can also promote inflammation that contributes to myopathy. However, the participatory immune components that link either of these stressors to functional decline in skeletal muscle are unknown. The intestinal microbiota has emerged as an environmental factor that can alter xenobiotic metabolism, inflammation and host metabolism. We sought to define aspects of the microbiota and specific innate immune components that connect triggers of inflammation during ageing or xenobiotic exposure.